{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:20:14Z","timestamp":1707524414933},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,18]]},"DOI":"10.7759\/cureus.18870","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T14:37:37Z","timestamp":1634654257000},"source":"Crossref","is-referenced-by-count":0,"title":["Mimicking an Intraluminal Lesion: A Case Report on Mantle Cell Lymphoma"],"prefix":"10.7759","author":[{"given":"Kosisochukwu J","family":"Ezeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obiora","family":"Ezeudemba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-764","article-title":"Racial differences in mantle cell lymphoma in the United States","volume":"14","author":"Wang Y","year":"2014","unstructured":"Wang Y, Ma S. Racial differences in mantle cell lymphoma in the United States. BMC Cancer. 2014, 14:764. 10.1186\/1471-2407-14-764","journal-title":"BMC Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo E","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011, 117:5019-32. 10.1182\/blood-2011-01-293050","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah CY","year":"2016","unstructured":"Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016, 34:1256-69. 10.1200\/JCO.2015.63.5904","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou Y","year":"2008","unstructured":"Zhou Y, Wang H, Fang W, et al.. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008, 113:791-8. 10.1002\/cncr.23608","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster E","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, et al.. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008, 111:558-65. 10.1182\/blood-2007-06-095331","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler CH","year":"2010","unstructured":"Geisler CH, Kolstad A, Laurell A, et al.. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010, 115:1530-3. 10.1182\/blood-2009-08-236570","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-776740","article-title":"SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma","volume":"130","author":"Balsas P","year":"2017","unstructured":"Balsas P, Palomero J, Eguileor \u00c1, et al.. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 2017, 130:501-13. 10.1182\/blood-2017-04-776740","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan J","year":"2011","unstructured":"Ruan J, Martin P, Furman RR, et al.. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011, 29:690-7. 10.1200\/JCO.2010.31.1142","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani RH","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, et al.. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013, 31:88-94. 10.1200\/JCO.2012.42.7906","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5393.5393","article-title":"Anti-CD19 chimeric antigen receptor T cells improve responses to chemotherapy-refractory mantle cell lymphoma: a case report","volume":"128","author":"Chen W","year":"2016","unstructured":"Chen W, Du X, Luo C, Zhang Q, Wang M. Anti-CD19 chimeric antigen receptor T cells improve responses to chemotherapy-refractory mantle cell lymphoma: a case report. Blood. 2016, 128:5393. 10.1182\/blood.V128.22.5393.5393","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer JN","year":"2017","unstructured":"Kochenderfer JN, Somerville RP, Lu T, et al.. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017, 35:1803-13. 10.1200\/JCO.2016.71.3024","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler ME","year":"2016","unstructured":"Goebeler ME, Knop S, Viardot A, et al.. Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016, 34:1104-11. 10.1200\/JCO.2014.59.1586","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/53515-mimicking-an-intraluminal-lesion-a-case-report-on-mantle-cell-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:37Z","timestamp":1707507097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/53515-mimicking-an-intraluminal-lesion-a-case-report-on-mantle-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.18870","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,18]]}}}